Rankings
▼
Calendar
URGN
UroGen Pharma Ltd.
$917M
Q3 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$6M
Net Income
-$8M
EPS (Diluted)
$-0.67
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$4M
Stock-Based Comp.
$513,000
Balance Sheet
Total Assets
$9M
Total Liabilities
$4M
Stockholders' Equity
$5M
Cash & Equivalents
$8M
← FY 2016
All Quarters
Q4 2016 →
URGN Q3 2016 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena